Ventracor is an international medical device company focused on commercialising the world's leading artificial heart?device, the VentrAssist Left Ventricular Assist Device (LVAD).
The VentrAssist is a new third generation implantable heart device primarily designed as an alternative to heart transplantation for people with cardiac failure.
It may also be used for patients waiting for heart transplants as a bridge to transplant or as a bridge to recovery.
"Our vision is to become the world's major supplier of cardiac assist systems and to improve the quality of life for people suffering congestive heart failure"
Ventracor Limited is listed on the Australian Stock Exchange (symbol ASX: VCR) and on the New York Stock Exchange (NYSE) in the form of American Depository Shares (symbol: VTCRY). There are 193 million shares held by close to 20,000 shareholders.
Ventracor is included in the Standard & Poor/Australian Stock Exchange Top 200 index - the S&P/ASX 200.